This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE 1)

This study has been terminated.
Information provided by (Responsible Party):
Bayer Identifier:
First received: February 8, 2010
Last updated: September 23, 2015
Last verified: November 2014
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.

Condition Intervention Phase
Acute Heart Failure Drug: Cinaciguat (BAY58-2667) Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Pulmonary Capillary Wedge Pressure [ Time Frame: 8 hours ]

Secondary Outcome Measures:
  • Cardiac index (CI) [ Time Frame: 8 hours and 48 hours ]
  • Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: Follow up (30 + 5 days) ]
  • Right atrial pressure (RAP) [ Time Frame: 8 hours and 48 hours ]

Enrollment: 12
Study Start Date: March 2010
Study Completion Date: February 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Cinaciguat (BAY58-2667)
Infusion of 150 µg/h during 48h
Experimental: Arm 2 Drug: Cinaciguat (BAY58-2667)
Infusion of 100 µg/h during 48h
Experimental: Arm 3 Drug: Cinaciguat (BAY58-2667)
Infusion of 50 µg/h during 48h
Placebo Comparator: Arm 4 Drug: Placebo
Infusion of placebo during 48h


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and non-pregnant, non-lactating female subjects, age >/= 18 years of age; or women without childbearing potential defined as postmenopausal women aged 55 years or older, women with bilateral tubal ligation, women with bilateral ovariectomy, and women with a hysterectomy
  • Subjects must have the clinical diagnosis of CHF made at least three months prior to enrollment
  • Subjects must experience worsening of both of the symptoms below leading to hospitalization at the time of entry into the study:

    • dyspnea and
    • clinical evidence of volume overload

Exclusion Criteria:

  • Acute de-novo heart failure
  • Acute myocardial infarction and/or myocardial infarction within 30 days
  • Valvular heart disease requiring surgical intervention during the course of the study
  • Heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease
  • Primary hypertrophic cardiomyopathy
  • Acute inflammatory heart disease, eg, acute myocarditis
  • Unstable angina requiring angiography
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01065077

  Hide Study Locations
United States, New Jersey
Ridgewood, New Jersey, United States, 07450
United States, North Carolina
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Cleveland, Ohio, United States, 44106
Fairfield, Ohio, United States, 45014
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19102
Philadelphia, Pennsylvania, United States, 19107
Linz, Oberösterreich, Austria, 4010
Wien, Austria, 1090
Zagreb, Croatia, 10000
Helsinki, Finland, 00029
Oulu, Finland, 90220
Greifswald, Mecklenburg-Vorpommern, Germany, 17475
Köln, Nordrhein-Westfalen, Germany, 50924
Homburg, Saarland, Germany, 66424
Erfurt, Thüringen, Germany, 99089
Jena, Thüringen, Germany, 07740
Haifa, Israel, 34362
Jerusalem, Israel, 91120
Tiberias, Israel, 31905
San Fermo della Battaglia, Como, Italy, 22020
Brescia, Italy, 25100
Ferrara, Italy, 44100
Mantova, Italy, 46100
Torino, Italy, 10126
Nagoya, Aichi, Japan, 460-0001
Kure, Hiroshima, Japan, 737-0023
Higashiibaraki, Ibaraki, Japan, 311-3193
Kawasaki, Kanagawa, Japan, 216-8511
Omura, Nagasaki, Japan, 856-8562
Bunkyo-ku, Tokyo, Japan, 113-8603
Shinagawa, Tokyo, Japan, 142-8666
Osaka, Japan, 543-0035
Gdansk, Poland, 80-211
Lodz, Poland, 91-347
Warszawa, Poland, 02-507
Warszawa, Poland, 04-628
Wroclaw, Poland, 50-981
Zabrze, Poland, 41-800
Zgorzelec, Poland, 59-900
Bucharest, Romania, 022328
Cluj-Napoca, Romania, 400001
Russian Federation
Krasnoyarsk, Russian Federation, 660022
Moscow, Russian Federation, 109263
Moscow, Russian Federation, 115093
Moscow, Russian Federation, 119881
Beograd, Serbia, 11000
Nis, Serbia, 18000
Sremska Kamenica, Serbia, 21204
Lucenec, Slovakia, 984 39
Martin, Slovakia, 036 59
Celje, Slovenia, 3000
Golnik, Slovenia, 4204
Ljubljana, Slovenia, 1000
Göteborg, Sweden, 413 45
Uppsala, Sweden, 751 85
Lugano, Ticino, Switzerland, 6900
Zürich, Switzerland, 8091
Bangkok, Thailand, 10400
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer